However, despite the promising outcomes observed with immunotherapy in certain cancers, not all patients exhibit a favorable response to ICIs, and the overall response rate (ORR) is influenced by tumor type and specific drugs, ranging from 10.9% for single-agent ipilimumab (monoclonal antibody (mAbs) targeting CTLA-4, anti-CTLA-4 mAb) in previously treated melanoma to 69% for pembrolizumab (anti-PD-1 mAb) in relapsed/refractory classic Hodgkin’s lymphoma (7–9). Here, PDCD1 is linked to neoplasm.